Personalis (NASDAQ:PSNL) Trading 8.7% Higher – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL)’s stock price traded up 8.7% on Friday . The stock traded as high as $18.40 and last traded at $18.35. 2,419,398 shares changed hands during trading, a decline of 8% from the average daily volume of 2,638,447 shares. The stock had previously closed at $16.88.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on PSNL shares. BTIG Research upped their price target on shares of Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a report on Monday, July 20th. Morgan Stanley raised their price objective on shares of Personalis from $9.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Zacks Research downgraded Personalis from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Lake Street Capital cut Personalis from a “buy” rating to a “hold” rating and set a $16.25 target price on the stock. in a report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Personalis presently has a consensus rating of “Hold” and a consensus target price of $14.25.

Personalis Trading Up 9.7%

The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -16.99 and a beta of 2.27. The company’s 50 day simple moving average is $13.12 and its 200-day simple moving average is $9.62.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). The firm had revenue of $22.36 million during the quarter, compared to analyst estimates of $16.69 million. Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. Sell-side analysts anticipate that Personalis, Inc. will post -1.07 EPS for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of the business’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,620,618.94. The trade was a 20.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,103,215.90. This represents a 29.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 435,032 shares of company stock valued at $5,599,929 over the last quarter. 4.20% of the stock is currently owned by insiders.

Institutional Trading of Personalis

A number of hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd increased its position in Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares in the last quarter. Deutsche Bank AG grew its stake in Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock worth $309,000 after buying an additional 1,655 shares during the period. Royal Bank of Canada increased its position in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares in the last quarter. Howland Capital Management LLC raised its stake in shares of Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after acquiring an additional 2,500 shares during the period. Finally, Intech Investment Management LLC raised its stake in shares of Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after acquiring an additional 3,851 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.